Efficacy of different protocols of greater occipital nerve block in treatment of migraine

Clinical trial on comparing efficacy of greater occipital nerve block with triamcinolone, lidocaine, triamcinolone with lidocaine and normal saline in treatment of migraine headache without aura

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017070334879N1

Enrollment

Registered

2017-08-10

Start date

2017-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. [Migraine without aura [common migraine

Interventions

Intervention 1: Intervention group 1: 20 mg of triamcinolone and normal saline (2.5 cc) is injected on each side of occipital tubercle with 3 or 5 cc syringe. Intervention 2: Intervention group 2: 2 c

Treatment - Drugs

Placebo

Intervention group 1: 20 mg of triamcinolone and normal saline (2.5 cc) is injected on each side of occipital tubercle with 3 or 5 cc syringe

Intervention group 2: 2 cc lidocaine of 2% and normal saline (2.5 cc) is injected on each side of occipital tubercle with 3 or 5 cc syringe

Intervention group 3: 20 mg of triamcinolone and 2cc of lidocaine 2% (2.5 cc) is injected on each side of occipital tubercle with 3 or 5 cc syringe

Control group: Normal saline (2.5 cc) is injected on each side of occipital tubercle with 3 or 5 cc syringe

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with episodic migraine without aura with attack frequency of more than 4 times per month; age between 18 and 65 Exclusion criteria: failure to obtain informed consent; prophylactic treatment started within last month; allergy to lidocaine; history of seizure; history of surgery in the occipital region; active infection in occipital region

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Attack frequency. Timepoint: just before and 1 and 2 months after intervention. Method of measurement: asked from patient and reported as attack per month.;Attack duration. Timepoint: just before and 1 and 2 months after intervention. Method of measurement: asked from patient and reported as attack duration.;Attack severity. Timepoint: just before and 1 and 2 months after intervention. Method of measurement: asked from patient and reported between 1 and 10.	—

Measure

Time frame

Attack frequency. Timepoint: just before and 1 and 2 months after intervention. Method of measurement: asked from patient and reported as attack per month.;Attack duration. Timepoint: just before and 1 and 2 months after intervention. Method of measurement: asked from patient and reported as attack duration.;Attack severity. Timepoint: just before and 1 and 2 months after intervention. Method of measurement: asked from patient and reported between 1 and 10.

—

Secondary

Measure	Time frame
Quality of life. Timepoint: just before and 1 and 2 months after intervention. Method of measurement: MSQ questionnaire and VAS scale.;Disability. Timepoint: just before and 1 and 2 months after intervention. Method of measurement: MIDAS questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mahsa Layegh

Neurology department, shariati hospital, Tehran university of medial sciences

layegh.mahsa@gmail.com+98 21 8490 2390

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 14, 2026